12:00 AM
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TroVax: Development discontinued

sanofi-aventis discontinued development of TroVax due to a reprioritization of its R&D portfolio and returned rights to Oxford BioMedica. Last year, an independent DSMB said TroVax would...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >